{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:37:37Z","timestamp":1793191057897,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","amjmed.com","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.amjmed.2024.11.007","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T02:36:38Z","timestamp":1731897398000},"page":"650-659.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-3059","authenticated-orcid":false,"given":"Michael","family":"Pollack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Rapsomaniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel M.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"M\u00fcllerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2024.11.007_bib0001","unstructured":"Global initiative for chronic obstructive lung disease. 2024 GOLD Report: global strategy for prevention, diagnosis and management of COPD. 2024. Available at: https:\/\/goldcopd.org\/wp-content\/uploads\/2024\/01\/GOLD-2024_v1.2-11Jan24_WMV-1.pdf. Accessed September 17, 2024."},{"issue":"12","key":"10.1016\/j.amjmed.2024.11.007_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global burden of chronic obstructive pulmonary disease through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0003","unstructured":"World Health Organization. The top 10 causes of death. 2024. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Accessed October 25, 2024."},{"issue":"11","key":"10.1016\/j.amjmed.2024.11.007_bib0004","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S2213-2600(23)00261-8","article-title":"COPD and multimorbidity: recognising and addressing a syndemic occurrence","volume":"11","author":"Fabbri","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/1753465817750524","article-title":"Defining the relationship between COPD and CVD: what are the implications for clinical practice?","volume":"12","author":"Morgan","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0006","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/COPD.S346591","article-title":"Frequency and severity of exacerbations of COPD associated with future risk of exacerbations and mortality: a UK Routine Health Care Data Study","volume":"17","author":"Whittaker","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0007","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/COPD.S438893","article-title":"Risk of death and cardiovascular events following an exacerbation of COPD: the EXACOS-CV US Study","volume":"19","author":"Daniels","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0008","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12931-023-02601-4","article-title":"Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands","volume":"24","author":"Swart","year":"2023","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0009","article-title":"Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany","volume":"11","author":"Vogelmeier","year":"2024","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"10.1016\/j.amjmed.2024.11.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02364-2022","article-title":"Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort","volume":"62","author":"Maclagan","year":"2023","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.amjmed.2024.11.007_bib0011","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/resp.13620","article-title":"Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD","volume":"24","author":"Reilev","year":"2019","journal-title":"Respirology"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0012","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2147\/COPD.S407085","article-title":"All-cause, cardiovascular and respiratory mortality in people with type 2 diabetes and chronic obstructive pulmonary disease (COPD) in England: a cohort study using the Clinical Practice Research Datalink (CPRD)","volume":"18","author":"Raslan","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0013","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s12325-024-02855-4","article-title":"Implications of cardiopulmonary risk for the management of COPD: a narrative review","volume":"41","author":"Singh","year":"2024","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.amjmed.2024.11.007_bib0014","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/15412555.2010.510160","article-title":"Mortality in COPD: causes, risk factors, and prevention","volume":"7","author":"Berry","year":"2010","journal-title":"COPD"},{"issue":"7","key":"10.1016\/j.amjmed.2024.11.007_bib0015","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1513\/AnnalsATS.202204-317ED","article-title":"Mind the gap: addressing cardiovascular disease in chronic obstructive pulmonary disease","volume":"19","author":"Wells","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0016","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/COPD.S329316","article-title":"Overcoming therapeutic inertia to reduce the risk of COPD exacerbations: four action points for healthcare professionals","volume":"16","author":"Singh","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2024.11.007_bib0017","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/eurheartj\/ehad669","article-title":"Exacerbating the burden of cardiovascular disease: how can we address cardiopulmonary risk in individuals with chronic obstructive pulmonary disease?","volume":"45","author":"Shrikrishna","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.amjmed.2024.11.007_bib0019","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0020","first-page":"33","article-title":"Mortality risk and serious cardiopulmonary events in moderate-to-severe COPD: post hoc analysis of the IMPACT trial","volume":"10","author":"Wells","year":"2023","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"5","key":"10.1016\/j.amjmed.2024.11.007_bib0021","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.amjmed.2024.11.007_bib0022","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0023","article-title":"Effect of triple therapy on car-diovascular and severe cardio pulmonary events in COPD: a post-hoc analysis of a randomized, double-blind, phase 3 clinical trial (ETHOS)","author":"Singh","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0024","article-title":"Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study)","volume":"10","author":"Deslee","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.36469\/001c.55635","article-title":"PROMETHEUS: long-term exacerbation and mortality benefits of implementing single-inhaler triple therapy in the US COPD population","volume":"10","author":"Criner","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"issue":"5","key":"10.1016\/j.amjmed.2024.11.007_bib0026","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","article-title":"Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain","volume":"162","author":"Alc\u00e1zar-Navarrete","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0027","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/COPD.S370540","article-title":"Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting","volume":"17","author":"Halpin","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.amjmed.2024.11.007_bib0028","doi-asserted-by":"crossref","first-page":"00950","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0029","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2147\/COPD.S302241","article-title":"Development and validation of a healthcare utilization-based algorithm to identify acute exacerbations of chronic obstructive pulmonary disease","volume":"16","author":"Mapel","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0030","unstructured":"Office for Human Research Protections. 2021. Available at: https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/45-cfr-46\/index.html Accessed May 31, 2024."},{"key":"10.1016\/j.amjmed.2024.11.007_bib0031","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CLEP.S129879","article-title":"Confounding in observational studies based on large health care databases: problems and potential solutions\u2014a primer for the clinician","volume":"9","author":"N\u00f8rgaard","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0032","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"9589","key":"10.1016\/j.amjmed.2024.11.007_bib0033","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: defining their cause and prevention","volume":"370","author":"Wedzicha","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0034","first-page":"199","article-title":"Hypoxemia in patients with COPD: cause, effects, and disease progression","volume":"6","author":"Kent","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0035","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221113647","article-title":"Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"M\u00fcllerov\u00e1","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1164\/rccm.201203-0455PP","article-title":"The relationship between lung inflammation and cardiovascular disease","volume":"186","author":"Eeden","year":"2012","journal-title":"Am J Respirat Crit Care Med"},{"issue":"5","key":"10.1016\/j.amjmed.2024.11.007_bib0037","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.21037\/jtd.2020.03.60","article-title":"Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients","volume":"12","author":"Aisanov","year":"2020","journal-title":"J Thorac Dis"},{"issue":"149","key":"10.1016\/j.amjmed.2024.11.007_bib0038","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2018","article-title":"Cardiovascular disease and COPD: dangerous liaisons?","volume":"27","author":"Rabe","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1147985","article-title":"Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: a prospective observational study in China","volume":"14","author":"Lin","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0040","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2147\/COPD.S85681","article-title":"Evaluating inhaler use technique in COPD patients","volume":"10","author":"Pothirat","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0041","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/COPD.S177213","article-title":"Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid\/long-acting \u03b2(2)-agonist via dry-powder inhalers and pressurized metered-dose inhalers","volume":"14","author":"Wittbrodt","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0042","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/COPD.S90155","article-title":"The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients","volume":"10","author":"Darb\u00e0","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0043","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2147\/COPD.S141409","article-title":"The comparative effectiveness of initiating fluticasone\/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study","volume":"12","author":"Jones","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"10.1016\/j.amjmed.2024.11.007_bib0044","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.rmed.2011.04.010","article-title":"Device type and real-world effectiveness of asthma combination therapy: an observational study","volume":"105","author":"Price","year":"2011","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.11.007_bib0045","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12931-023-02534-y","article-title":"Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging","volume":"24","author":"Usmani","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.amjmed.2024.11.007_bib0046","unstructured":"Optum. Optum claims data. Available at: https:\/\/www.optum.com\/en\/business\/life-sciences\/real-world-data\/claims-data.html. Accessed 28 October, 2024."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324007599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324007599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T23:16:16Z","timestamp":1742253376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934324007599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0002934324007599"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.11.007","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}